Investor Presentation First Nine Months of 2022
10
Investor presentation First nine months of 2022
Rare disease sales increased by 2% driven by International
Operations
Reported Rare disease sales
Rare disease sales driven by global commercial execution
DKK
billion
Growth at CER
18
2%
6%
6%
12
6
Rare disease sales increase is driven by:
9%
6%
-6%
•
3% sales decline in North America Operations
•
4% sales growth in International Operations
Rare blood disorders
0
Total1
Rare
blood
disorders²
Haem.
A
Haem.
B
Novo-
Rare
SevenⓇ endocrine
disorders³
Rare blood disorders sales increased by 6%, driven by:
.
NovoSevenⓇ performance
.
Uptake of launch products EsperoctⓇ and Refixia®
.
Rare endocrine disorders sales decreased by 6% driven by:
North America Operations sales declined by 13%
Novo Nordisk is the leading company in the global human growth
disorder market with a value market share of ~36% which is
comparable to last year
1 Total includes "Other Rare disease", which consists of primarily Vagifem® and Activelle®: 2 Comprises NovoSeven®, Novo Eight®, Esperoct®, Refixia® and NovoThirteenⓇ; 3 Primarily NorditropinⓇ
Note: NovoThirteenⓇ is not shown for Rare blood disorders breakdown, only for the total bar.
Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates
Novo NordiskⓇView entire presentation